Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21

Kimmich, C. R., Terzer, T., Benner, A., Hansen, T., Carpinteiro, A., Dittrich, T., … Hegenbart, U. (2021, July 1). Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21. American Journal of Hematology. John Wiley and Sons Inc. https://doi.org/10.1002/ajh.26191